ALEXANDRIA REAL ESTATE EQUITIES, INC.
ALEXANDRIA REAL ESTATE EQUITIES, INC. (ARE) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.
• Alexandria owns and develops life-science laboratory campuses leased to biotech, pharma, and research tenants, concentrated in clusters like Boston, San Francisco, and San Diego where lab space is hardest to replace. • The earnings line is holding even as the market deteriorates: first-quarter 2026 funds from operations were $1.73 per share and management reaffirmed full-year guidance of $6.40, while occupancy slipped to 87.7%. • The defining risk is the life-science downturn itself; the quart
Is ARE overvalued? See what's priced in →
548 institutional managers reported holding ARE in 13F filings for the quarter ended 2026-03-31. Together they hold about 85% of the company; the top 10 hold 50%. 76 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 6.0M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (2.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ARE's share count grew 17% over the past five years even with $258.29M spent on repurchases. It pays a dividend, and has paid one every year in our records (17 and counting), raised 10 years straight; the current rate is $4.68 a share annually. Cash returned over the past three years: $2.36B in dividends and $258.29M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ARE over the trailing three years: 2025: 1 buy totaling $141k; 2026: 2 buys totaling $1.35M. 31 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ARE's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-25 | +0.4% | -20.4% |
| 2023-10-24 | +0.5% | +35.1% |
| 2024-01-30 | -2.5% | +2.3% |
| 2024-04-23 | +3.3% | -2.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ARE's latest 8-K filings: 2026-07-09 (items 1.01, 2.03); 2026-05-14 (items 5.07, 9.01); 2026-04-27 (items 2.02, 9.01); 2026-03-31 (items 5.03, 9.01); 2026-02-25 (items 1.01, 2.03, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.